Phase I clinical trials in NSCLC patients have also been conducted with encouraging clinical results [9
]. For phase I and II clinical tri-als, mAb-Racotumomab was produced in mice ascites, a common practice in the 1990s for small scale antibody production.
We developed a new bioreactor-based process using protein-free media for the production of mAb-Racotumomab.
Given the increase in production volume, it was necessary to